BMS-986315 / BMS - LARVOL DELTA

A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - P2 | N=1 | Terminated | Sponsor: Bristol-Myers Squibb | Completed ➔ Terminated; Business objectives have changed

Trial termination • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=44 | Terminated | Sponsor: Bristol-Myers Squibb | N=308 ➔ 44 | Trial completion date: May 2025 ➔ Aug 2024 | Active, not recruiting ➔ Terminated; The Study has been terminated due to non-safety reasons; business objectives have changed.

Combination therapy • Enrollment change • Metastases • Monotherapy • Trial completion date • Trial termination • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - P2 | N=1 | Completed | Sponsor: Bristol-Myers Squibb | Active, not recruiting ➔ Completed | N=196 ➔ 1 | Trial completion date: Oct 2027 ➔ Aug 2024 | Trial primary completion date: Oct 2026 ➔ Aug 2024

Combination therapy • Enrollment change • Metastases • Trial completion • Trial completion date • Trial primary completion date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=308 | Active, not recruiting | Sponsor: Bristol-Myers Squibb | Trial primary completion date: Apr 2024 ➔ Aug 2024

Combination therapy • Metastases • Monotherapy • Trial primary completion date • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - P2 | N=196 | Active, not recruiting | Sponsor: Bristol-Myers Squibb | Recruiting ➔ Active, not recruiting

Combination therapy • Enrollment closed • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=308 | Active, not recruiting | Sponsor: Bristol-Myers Squibb | Recruiting ➔ Active, not recruiting

Enrollment closed • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - P2 | N=196 | Recruiting | Sponsor: Bristol-Myers Squibb | Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - P2 | N=196 | Not yet recruiting | Sponsor: Bristol-Myers Squibb

Combination therapy • Metastases • New P2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=308 | Recruiting | Sponsor: Bristol-Myers Squibb | Trial completion date: Jun 2023 ➔ May 2025 | Trial primary completion date: Jun 2023 ➔ Apr 2024

Combination therapy • Monotherapy • Trial completion date • Trial primary completion date • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=308 | Recruiting | Sponsor: Bristol-Myers Squibb | Trial completion date: Oct 2024 ➔ Jun 2023

Combination therapy • Monotherapy • Trial completion date • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2; N=308; Recruiting; Sponsor: Bristol-Myers Squibb; Trial completion date: Apr 2024 ➔ Oct 2024; Trial primary completion date: Apr 2024 ➔ Jul 2023

Combination therapy • Monotherapy • Trial completion date • Trial primary completion date • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2; N=308; Recruiting; Sponsor: Bristol-Myers Squibb; Not yet recruiting ➔ Recruiting

Combination therapy • Enrollment open • Monotherapy • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - P1/2; N=308; Not yet recruiting; Sponsor: Bristol-Myers Squibb

Combination therapy • Monotherapy • New P1/2 trial • Genito-urinary Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Thoracic Cancer • Urothelial Cancer